Trial intelligence / Profile preview

EVIDENCE: Nebivolol vs Atenolol in Early Vascular Disease

NCT01522950Phase 2

Key facts

Status: Completed
Start: May 2010
Primary completion: Oct 2016
Countries: 1
Sponsor: University of Minnesota
Modality: Small Molecules

Drugs: nebivolol
Conditions: hypertension (HTN)

Overview

Phase 2, randomised, double-blind trial of nebivolol in hypertension (HTN) (3 arms), sponsored by University of Minnesota. Primary endpoint: Change in Small Artery Elasticity (C2) at 9 months. Started May 2010; status: completed.

Design

3 arms

Study design: RandomizedDouble-blind

Nebivolol
Nebivolol 5 mg daily for 1 month, then 10 mg daily for 8 months
Atenolol
Atenolol 25 mg daily for 1 month, then 50 mg daily for 8 months
Placebo
Placebo daily

Who it enrols

Patients with borderline blood pressure (120-145/80-90 mm Hg) and impaired small artery elasticity, treatment-naive for 30 days. Excludes diabetes, known CVD, and beta-blocker intolerance.

Endpoints

Primary

Change in Small Artery Elasticity (C2)9 months

Secondary

Change in Large Artery Elasticity (C1)9 months
Change in Systolic Blood Pressure9 months
Change in Diastolic Blood Pressure9 months

Beyond the preview

Go deeper on NCT01522950.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01522950.